Recent trends in the antibiotic resistance of Helicobacter pylori in patient with dyspepsia

Simple item page
dc.contributor.authorBuran T.
dc.contributor.authorSürücüoǧlu S.
dc.contributor.authorKurutepe S.
dc.contributor.authorGazi H.
dc.date.accessioned2024-07-22T08:04:19Z
dc.date.available2024-07-22T08:04:19Z
dc.date.issued2022
dc.description.abstractThe aim of this study was to determine the resistance status and to identify the point mutations conferring resistance to clarithromycin and fluoroquinolones among dyspeptic patients in Manisa, Turkey. The study included a sample of 140 patients with an indication for upper gastrointestinal endoscopy randomly selected from 2100 dyspeptic patients attending to the Gastroenterology and Endoscopy Unit at Manisa Celal Bayar University Hafsa Sultan Hospital between April 2016 and May 2018. A commercially available GenoType Helico DR test was used to detect the presence of Helicobacter pylori and mutations associated with resistance to clarithromycin and fluoroquinolones in biopsy specimens. In total, 116 (82.9%) of 140 biopsies obtained from the same number of dyspeptic patients were positive for H pylori and 82 (approximately 71%) of them harbored resistance mutations in 23SrRNA and/or gyrA. Resistance to clarithromycin, levofloxacin, or both were detected in 43.1% (50/116), 27.6% (32/116), and 16/116 (13.8%) of tested biopsies, respectively. The most common mutation conferring resistance to clarithromycin was A2147G (96%, 48/50). Resistance to fluoroquinolones was frequently due to mutation in codon 91 and the most common mutation detected was D91G (34.4%). Heteroresistance patterns were observed in 48.0% (24/50) of clarithromycin-resistant samples and 28.1% (9/32) of levofloxacin-resistant samples. The resistance rates and detected mutations in this study are in line with the country data. However, to achieve better H pylori eradication and to prevent the spread of multidrug-resistant strains in Turkey, the molecular-based susceptibility tests should be considered routinely. Further studies are needed to determine the various mutations among resistant strains. © 2022 Lippincott Williams and Wilkins. All rights reserved.
dc.identifier.DOI-ID10.1097/MD.0000000000029801
dc.identifier.issn00257974
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12658
dc.language.isoEnglish
dc.publisherLippincott Williams and Wilkins
dc.rightsAll Open Access; Gold Open Access; Green Open Access
dc.subjectAnti-Bacterial Agents
dc.subjectClarithromycin
dc.subjectDrug Resistance, Bacterial
dc.subjectDyspepsia
dc.subjectFluoroquinolones
dc.subjectHelicobacter Infections
dc.subjectHelicobacter pylori
dc.subjectHumans
dc.subjectLevofloxacin
dc.subjectMicrobial Sensitivity Tests
dc.subjectclarithromycin
dc.subjectlevofloxacin
dc.subjectquinolone derivative
dc.subjectRNA 23S
dc.subjectantiinfective agent
dc.subjectclarithromycin
dc.subjectquinolone derivative
dc.subjectadult
dc.subjectantibiotic resistance
dc.subjectantibiotic sensitivity
dc.subjectArticle
dc.subjectbacterial mutation
dc.subjectbacterial strain
dc.subjectbacterium detection
dc.subjectcodon
dc.subjectcontrolled study
dc.subjectdyspepsia
dc.subjectfemale
dc.subjectgastrointestinal endoscopy
dc.subjectgenotype
dc.subjectHelicobacter infection
dc.subjectHelicobacter pylori
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectlogistic regression analysis
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmiddle aged
dc.subjectpoint mutation
dc.subjectprevalence
dc.subjectstomach biopsy
dc.subjectstudy design
dc.subjecttertiary care center
dc.subjectTurkey (republic)
dc.subjectuniversity hospital
dc.subjectantibiotic resistance
dc.subjectdyspepsia
dc.subjectgenetics
dc.subjectHelicobacter infection
dc.subjectmicrobial sensitivity test
dc.titleRecent trends in the antibiotic resistance of Helicobacter pylori in patient with dyspepsia
dc.typeArticle

Files

Collections

Scopus Koleksiyonu